Human circulating monocytes can express receptor activator of nuclear factor-κB ligand and differentiate into functional osteoclasts without exogenous stimulation

Immunology and Cell Biology

Volumn 86, Issue 5, 2008, Pages 453-459

  Seta, Noriyuki ^a   Okazaki, Yuka ^a   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Monocyte; Monocyte derived multipotential cell; Osteoclast; Receptor activator of nuclear factor B ligand

Indexed keywords

CALCITONIN RECEPTOR; CATHEPSIN K; CD14 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPROTEGERIN;

ARTICLE; BRAIN SLICE; CELL DENSITY; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYME CELL; MONOCYTE; OSTEOCLAST; PROTEIN EXPRESSION;

CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; MONOCYTES; OSTEOCLASTS; PHENOTYPE; RANK LIGAND;

EID: 46749126610     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.4     Document Type: Article

References (25)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
2. Miyamoto T, Suda T. Differentiation and function of osteoclasts. Keio J Med 2003; 52: 1-7.
3. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999; 106: 167-170.
4. Fujikawa Y, Quinn JMW, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996; 139: 4058-4060.
5. Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillespie NT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 144-150.
6. + monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003; 74: 833-845.
7. Seta N, Kuwana M. Human circulating monocytes as multipotential progenitors. Keio J Med 2007; 56: 41-47.
8. + monocytes. Stem Cell Dev 2005; 14: 676-686.
9. + monocytes. Immunol Cell Biol 2006; 84: 209-217.
10. Kuwana M, Okazaki Y, Kodama H, Satoh T, Kawakami Y, Ikeda Y. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006; 24: 2733-2743.
11. Drake HF, Dodds RA, James IE, Connor JR, Debouck C, Richardson S et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996; 271: 12511-12516.
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
13. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-1337.
14. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005; 202: 345-351.
15. Balir JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Oncology 2006; 3: 41-49.
16. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-269.
17. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 1047-1054.
18. Brach MA, Arnold C, Kiehntopf M, Gruss HJ, Herrmann F. Transcriptional activation of the macrophage colony-stimulating factor gene by IL-2 is associated with secretion of bioactive macrophage colony-stimulating factor protein by monocytes and involves activation of the transcription factor NF-kappa B. J Immunol 1993; 150: 5535-5543.
19. Arai F, Miyamoto T, Ohneda O, Inada T, Suda T, Brasel K et al. Commitment and differentiation of osteoclast precursor cells by sequential expression of c-Fms and receptor activation of nuclear factor κB (RANK) receptors. J Exp Med 1999; 190: 1741-1754.
20. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
21. Zimolo Z, Wesolowski G, Tanaka H, Hyman JL, Hoyer JR, Rodan GA. Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells. Am J Physiol 1994; 266: C376-C381.
22. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 2005; 40: 287-293.
23. Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990; 43: 997-1003.
24. Yu X, Huang Y, Osdoby PC, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004; 19: 2065-2077.
25. Cas is involved in actin organization in osteoclasts. J Biol Chem 1998; 273: 11144-11149.